论文部分内容阅读
溶血栓疗法虽然已在临床应用多年,但至今仍未占明确地位。本文简述了链激酶和尿激酶治疗周围动脉阻塞、静脉血栓形成、肺动脉栓塞和心肌梗塞的近况。溶血栓药物可以静脉或动脉内给药。链激酶(SK)首次剂量25万u,以后连续静滴10万u/小时。尿激酶(UK)首次剂量为5,500u/kg体重(原文为,2,000u/lb体重),以后连续静滴5,500u/kg体重·小时。实验
Although thrombolytic therapy has been in clinical use for many years, but so far still not clear the position. This article describes the status of streptokinase and urokinase for the treatment of peripheral arterial occlusion, venous thrombosis, pulmonary embolism and myocardial infarction. Thrombolytic drugs can be administered intravenously or intra-arterially. Streptokinase (SK) first dose of 250,000 u, after continuous infusion of 100,000 u / hour. Urokinase (UK) first dose of 5,500u / kg body weight (2,000u / lb body weight, then continuous intravenous infusion of 5,500u / kg body weight per hour. experiment